Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. Naggie S, et al. Among authors: marks k. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21. N Engl J Med. 2015. PMID: 26196665 Free PMC article. Clinical Trial.
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ; North American Liver Cancer in HIV Study Group. Bräu N, et al. Among authors: marks k. J Hepatol. 2007 Oct;47(4):527-37. doi: 10.1016/j.jhep.2007.06.010. Epub 2007 Jul 19. J Hepatol. 2007. PMID: 17692986
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ; A5239 Team. Marks KM, et al. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):345-9. doi: 10.1097/QAI.0000000000000073. J Acquir Immune Defic Syndr. 2014. PMID: 24525470 Free PMC article. Clinical Trial.
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R; AIDS Clinical Trials Group (ACTG) A5327 Study Team. Naggie S, et al. Among authors: marks km. Clin Infect Dis. 2017 Apr 15;64(8):1035-1042. doi: 10.1093/cid/cix025. Clin Infect Dis. 2017. PMID: 28329053 Free PMC article. Clinical Trial.
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ. MacBrayne CE, et al. J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146. J Antimicrob Chemother. 2018. PMID: 29746648 Free PMC article. Clinical Trial.
Management of Hepatitis C in 2019.
Marks K, Naggie S. Marks K, et al. JAMA. 2019 Jul 23;322(4):355-356. doi: 10.1001/jama.2019.5353. JAMA. 2019. PMID: 31099822 No abstract available.
487 results